A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2017
At a glance
- Drugs Masitinib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors AB Science
- 15 Jun 2017 This trial has been suspended in Germany.
- 10 Jun 2017 This trial has been suspended in Netherlands.
- 10 Jun 2017 Biomarkers information updated